Pediatric inpatients with inflammatory bowel disease (IBD) are rarely considered for thromboprophylaxis because of concerns about safety and underappreciation of thrombotic risk. We characterized thromboembolism (TE) in children and young adults with inflammatory bowel disease (IBD) at a single tertiary care hospital.
We performed a retrospective review of an inpatient billing database for all IBD admissions with colonic involvement and an anticoagulation database for thrombotic complications from 2006 to 2011.
Of 532 patients admitted with IBD with colonic involvement, 10 (1.9%) had TE (9 venous, 1 arterial), 2 of whom had recurrent thrombosis. Many of the events resulted in considerable morbidity, including 4 cerebrovascular events and 2 pulmonary emboli. Established risk factors in IBD colitis inpatients with TE included: indwelling catheter (4/10), first-degree family member with TE (2/10), hereditary thrombophilia (3/10), smoking (1/10), oral contraceptive (1/5 females), and thalidomide (1/10). Additionally, most (8/10) patients had acquired thrombophilia, mostly elevation of factor VIII and anticardiolipin antibodies. Patients with IBD and TE received therapeutic anticoagulation without significantly increased bleeding. Thrombus resolution was documented in 7 cases, persistence in 2 cases and recurrence in 2 cases.
Pediatric inpatients hospitalized with IBD with colonic involvement have increased risk of TE, including complications of pulmonary embolism, recurrence, persistence, and indefinite long-term anticoagulation. Therapeutic anticoagulation in patients with IBD with active colitis appears safe. We identified both inherited thrombophilias and acquired risk factors in patients with IBD and TE. We presently use risk stratification and recommend prophylactic anticoagulation in high-risk patients.
*Division of Gastroenterology
†Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA.
Address correspondence and reprint requests to Naamah L. Zitomersky, MD, Division of Gastroenterology, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115 (e-mail: firstname.lastname@example.org).
Received 7 March, 2013
Accepted 20 May, 2013
N.L.Z. is supported by Children's Hospital Boston Career Development Award; NASPGHAN CDHNF Fellow to Faculty Transition Award in Inflammatory Bowel Diseases. A.E.L. and J.R.L. are supported by a Patient Provider Quality Initiative Grant. B.J.A. is supported by the Rasmussen Family Fund. C.C.T. is supported by NIH/NHLBI K08 HL089509.
The authors report no conflicts of interest.